In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia

Recent studies suggest that treatment with SGLT-2 inhibitors can reduce hepatic lipid storage and ameliorate non-alcoholic fatty liver disease (NAFLD) development beyond their glycemic benefits. However, the exact mechanism involved is still unclear. We investigated the hepatic metabolic effect of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hüttl, Martina, Markova, Irena, Miklankova, Denisa, Zapletalova, Iveta, Poruba, Martin, Haluzik, Martin, Vaněčkova, Ivana, Malinska, Hana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584090/
https://www.ncbi.nlm.nih.gov/pubmed/34768942
http://dx.doi.org/10.3390/ijms222111513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584090/
https://www.ncbi.nlm.nih.gov/pubmed/34768942
http://dx.doi.org/10.3390/ijms222111513

Ejemplares similares